Royalty Pharma price to sales ratio RPRX
Market value divided by revenue over the last twelve months, since 2021.
- Today, Nov 3, 2026
- 15.3×
- 6-year median
- 9.8×
- Against its 6-year history
- 100th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 6.5× to 15.2×
- Peer median
- 5.7×
Royalty Pharma's price to sales ratio is 15.3× as of Nov 3, 2026.
That is above its 6-year median of 9.8×, higher than on 100% of days in the last 6 years.
Over that time it ranged from 6.5× in Dec 2024 to 15.2× in Oct 2026.
The median for 10 healthcare stocks of a similar size is 5.7×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 15.1× | 9.5× | 15.2× |
| 2025 | 9.6× | 6.7× | 9.8× |
| 2024 | 6.6× | 6.5× | 7.9× |
| 2023 | 7.2× | 6.7× | 10.6× |
| 2022 | 10.7× | 10.1× | 11.9× |
| 2021 | 10.6× | 9.6× | 13.4× |
Against its peers
Companies in Healthcare nearest Royalty Pharma's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| RPRXRoyalty Pharma | 15.3× |
| BIIBBiogen | 3.7× |
| GEHCGE HealthCare Technologies | 1.7× |
| ONCBeOne Medicines | 6.6× |
| IQVIQVIA | 2.5× |
| ZTSZoetis | 3.6× |
| ILMNIllumina | 8.0× |
| MTDMettler-Toledo International | 8.3× |
| RMDResMed | 5.7× |
| WATWaters | 10.0× |
| MDLNMedline | n/m |
| Peer median | 5.7× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Royalty Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.